/

BIAF

bioAffinity Technologies, Inc.Closed

3.63−0.28 −7.05%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 3.52 −2.90%

Open

3.50

Prev close

3.90

Day range

3.233.74

52-week range

3.2380.70

Volume

885.65K0.24×

Mkt cap

4.65M

P/E ttm

—

Fwd P/E

-6.04

EPS ttm

-109.35

Div yield

0.00%

Earnings

—

From 52w high

−95.51%

Price Chart

Yahoo Finance · delayed

BIAFOct 13, 2026O 3.52H 3.74L 3.23C 3.63−0.28 (−7.05%)Vol 887.30K

SMA 507.11
SMA 20020.25

1Y change −90.91% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

BIAF bioAffinity Technologies, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −40.18%
1 month: −54.40%
3 months: −65.91%
6 months: −91.40%
Year to date: −79.52%
1 year: −90.91%

Valuation & ownership

Market cap: 4.65M
Enterprise value: 962.27K
P/E (ttm): —
Forward P/E: -6.04
PEG ratio: —
Price / book: 0.43
Price / sales (ttm): 0.79
EV / EBITDA: -0.08
EPS (ttm): -109.35
EPS (forward): -0.6000
Beta (5y monthly): -1.25
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 1.28M
Float: 536.75K
Short % of float: 9.95%
Short ratio (days): 0.01
Held by insiders: 0.75%
Held by institutions: 5.05%
Avg volume (3m): 3.74M
50-day average: 7.21
200-day average: 20.33
52-week change: −90.91%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 33.9
vs 50-day SMA: −48.99%
vs 200-day SMA: −82.10%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 38.92%
Realised vol (20d, ann.): 235.8%
From 52-week high: −95.51%
From 52-week low: +12.23%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): 5.90M
Revenue growth (yoy): +19.00%
Earnings growth (yoy): —
Gross margin: 34.61%
Operating margin: -220.77%
Profit margin: -257.33%

DES

About bioAffinity Technologies, Inc.

Yahoo Finance profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

Sector: Healthcare
Industry: Diagnostics & Research
Employees: 57
Headquarters: San Antonio, TX, United States
Website: bioaffinitytech.com
Officers: Mr. Steven Girgenti Founder & Executive Chairman of the Board
Ms. Maria Zannes J.D. Founder, President, CEO & Director
Mr. James Michael Edwards CPA, M.B.A. Chief Financial Officer

SEAS

Seasonality · BIAF

2022–2026 · monthly returns

Strongest month Apr +35.08%Weakest month Dec −24.64%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-3.4	-7.0	261.3	-35.1	-32.8	-51.4	-22.8	-51.5	43.9	-44.7			−79.5%
2025	-16.5	-34.2	-48.0	80.8	-40.4	2.5	10.5	-23.7	-59.2	-17.2	-38.8	-21.3	−95.7%
2024	6.7	47.8	-12.9	21.3	-2.0	-10.0	15.3	-39.8	38.7	-31.3	-15.0	-25.1	−38.1%
2023	63.1	-34.9	11.2	3.2	-6.2	0.0	-3.8	-1.7	-32.7	8.4	31.5	-11.4	−8.1%
2022										-2.1	-5.3	-40.7	−45.0%

INSD

Insider Activity · BIAF

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jan 9, 2025	Girgenti StevenOfficer and Director	—	14.8K	—
Jan 9, 2025	Edwards James Michael CpaChief Financial Officer	—	6.2K	—
Jan 9, 2025	Zannes Timothy PeterGeneral Counsel	—	8.6K	—
Jan 9, 2025	Reveles Xavier TrinidadChief Operating Officer	—	21.6K	—
Jan 9, 2025	Zannes MariaChief Executive Officer	—	37K	—
Nov 4, 2024	Edwards James Michael CpaChief Financial Officer	—	100K	—

BIAF

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

BIAF

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About bioAffinity Technologies, Inc.

Seasonality · BIAF

Insider Activity · BIAF

Congress Trades · BIAF

Investors Holding BIAF

Investors Holding BIAF

Congress Trades · BIAF

Insider Activity · BIAF

Seasonality · BIAF

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About bioAffinity Technologies, Inc.

Earnings & Dividends

News